amifampridine has been researched along with Diaphragmatic Paralysis in 1 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradford, AB | 1 |
| Machamer, JB | 1 |
| Russo, TM | 1 |
| McNutt, PM | 1 |
1 other study available for amifampridine and Diaphragmatic Paralysis
| Article | Year |
|---|---|
3,4-diaminopyridine reverses paralysis in botulinum neurotoxin-intoxicated diaphragms through two functionally distinct mechanisms.
Topics: 4-Aminopyridine; Amifampridine; Animals; Botulinum Toxins, Type A; Diaphragm; Male; Mice; Mice, Inbr | 2018 |